JP2010510784A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010510784A5 JP2010510784A5 JP2009538639A JP2009538639A JP2010510784A5 JP 2010510784 A5 JP2010510784 A5 JP 2010510784A5 JP 2009538639 A JP2009538639 A JP 2009538639A JP 2009538639 A JP2009538639 A JP 2009538639A JP 2010510784 A5 JP2010510784 A5 JP 2010510784A5
- Authority
- JP
- Japan
- Prior art keywords
- her3
- receptor
- antibody
- sample
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86124306P | 2006-11-28 | 2006-11-28 | |
| US60/861,243 | 2006-11-28 | ||
| EP06024658 | 2006-11-28 | ||
| EP06024658.4 | 2006-11-28 | ||
| PCT/EP2007/010335 WO2008064884A1 (en) | 2006-11-28 | 2007-11-28 | Activated her3 as a marker for predicting therapeutic efficacy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010510784A JP2010510784A (ja) | 2010-04-08 |
| JP2010510784A5 true JP2010510784A5 (https=) | 2011-01-20 |
| JP5656406B2 JP5656406B2 (ja) | 2015-01-21 |
Family
ID=38961070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009538639A Active JP5656406B2 (ja) | 2006-11-28 | 2007-11-28 | 治療効力を予測するためのマーカーとしての活性化ｈｅｒ３ |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20100047829A1 (https=) |
| EP (2) | EP2097754B2 (https=) |
| JP (1) | JP5656406B2 (https=) |
| AU (1) | AU2007324868B2 (https=) |
| CA (1) | CA2670522C (https=) |
| WO (1) | WO2008064884A1 (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
| KR101598229B1 (ko) | 2007-02-16 | 2016-02-26 | 메리맥 파마슈티컬즈, 인크. | Ｅｒｂｂ3에 대한 항체 및 이의 용도 |
| SI2132573T1 (sl) | 2007-03-02 | 2014-07-31 | Genentech, Inc. | Napovedovanje odziva na inhibitor dimerizacije HER na osnovi nizke ekspresije HER3 |
| EP2179291B1 (en) | 2007-07-13 | 2014-10-22 | Nestec S.A. | Drug selection for lung cancer therapy using antibody-based arrays |
| AU2009219437B2 (en) | 2008-02-25 | 2014-10-16 | Nestec S.A. | Drug selection for breast cancer therapy using antibody-based arrays |
| EP2138511A1 (en) * | 2008-06-27 | 2009-12-30 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | HER3 as a determinant for the prognosis of melanoma |
| WO2010019952A2 (en) | 2008-08-15 | 2010-02-18 | Merrimack Pharmaceuticals, Inc. | Methods, systems and products for predicting response of tumor cells to a therapeutic agent and treating a patient according to the predicted response |
| WO2010056406A1 (en) | 2008-11-12 | 2010-05-20 | The United State Of America, As Represented By The Secretary, Department Of Health & Human Services | Use of erbb4 as a prognostic and therapeutic marker for melanoma |
| US20120270745A1 (en) * | 2009-07-15 | 2012-10-25 | Prometheus Laboratories Inc. | Drug selection for cancer therapy by profiling signal transduction proteins in ascites or pleural efflux samples |
| JP5795311B2 (ja) | 2009-07-15 | 2015-10-14 | ネステク ソシエテ アノニム | 抗体ベースのアレイを使用する胃癌療法のための薬物選択 |
| RS54795B1 (sr) | 2009-12-22 | 2016-10-31 | Roche Glycart Ag | Anti-her3 antitela i njihova korišćenja |
| KR101798679B1 (ko) | 2010-03-11 | 2017-11-16 | 메리맥 파마슈티컬즈, 인크. | ３중 음성 및 기저형 유방암 치료 시의 ｅｒｂｂ３ 저해제의 용도 |
| US20110318336A1 (en) * | 2010-03-29 | 2011-12-29 | George Mason Intellectual Properties, Inc. | Identification and Treatment of Aggressive Lung Cancer Tumors |
| PH12013500064A1 (en) | 2010-07-09 | 2013-03-11 | Exelixis Inc | Combinations of kinase inhibitors for the treatment of cancer |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
| EP2751562B1 (en) | 2011-09-02 | 2015-09-16 | Nestec S.A. | Profiling of signal pathway proteins to determine therapeutic efficacy |
| ES2670651T3 (es) * | 2011-10-04 | 2018-05-31 | Expression Pathology, Inc. | Ensayo de SRM/MRM para determinar la proteína ERBB-4 del receptor de tirosina-proteína quinasa (HER4) |
| DK2797957T3 (da) | 2011-11-23 | 2019-09-23 | Medimmune Llc | Bindingsmolekyler specifikke for her3 og anvendelser deraf |
| AR094403A1 (es) | 2013-01-11 | 2015-07-29 | Hoffmann La Roche | Terapia de combinación de anticuerpos anti-her3 |
| KR101524915B1 (ko) * | 2013-05-10 | 2015-06-02 | 포항공과대학교 산학협력단 | 타이로신 인산화효소를 감지하는 형광 프로브 및 이의 용도 |
| US11305012B2 (en) | 2013-09-24 | 2022-04-19 | Medimmune, Llc | Binding molecules specific for HER3 and uses thereof |
| EP3087394A2 (en) | 2013-12-27 | 2016-11-02 | Merrimack Pharmaceuticals, Inc. | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies |
| WO2015157634A1 (en) | 2014-04-11 | 2015-10-15 | Kolltan Pharmaceuticals, Inc. | Anti-erbb antibodies and methods of use thereof |
| US10184006B2 (en) | 2015-06-04 | 2019-01-22 | Merrimack Pharmaceuticals, Inc. | Biomarkers for predicting outcomes of cancer therapy with ErbB3 inhibitors |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5183884A (en) * | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US5804396A (en) * | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| DE69736806T3 (de) | 1996-03-27 | 2015-10-08 | Genentech, Inc. | ErbB3 ANTIKÖRPER |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| AUPQ105799A0 (en) | 1999-06-18 | 1999-07-08 | Victor Chang Cardiac Research Institute, The | Cell growth inhibition |
| US6277640B1 (en) * | 2000-07-31 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Antisense modulation of Her-3 expression |
| EP1531842A4 (en) * | 2000-12-22 | 2007-03-07 | Dana Farber Cancer Inst Inc | REGULATION OF CELL GROWTH BY MUC1 |
| US7125680B2 (en) * | 2001-07-27 | 2006-10-24 | The Regents Of The University Of California | Methods and materials for characterizing and modulating interaction between heregulin and HER3 |
| EP1283053A1 (en) | 2001-08-09 | 2003-02-12 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Inhibitors of HER3 activity |
| WO2003097854A2 (en) * | 2002-05-17 | 2003-11-27 | Sugen, Inc. | Novel biomarkers of tyrosine kinase inhibitor exposure and activity in mammals |
| DE60310922T2 (de) * | 2002-06-05 | 2007-10-11 | Cedars-Sinai Medical Center, Los Angeles | Gefitinib (iressa) zur behandlung von krebs |
| JP4443407B2 (ja) | 2002-07-25 | 2010-03-31 | アクララ バイオサイエンシーズ， インコーポレイテッド | レセプターオリゴマー形成の検出 |
| EP1613205B1 (en) | 2003-04-01 | 2013-04-24 | Monogram BioSciences, Inc. | Erbb surface receptor complexes as biomarkers |
| CA2527680A1 (en) * | 2003-05-30 | 2005-06-02 | Astrazeneca Uk Limited | Markers for responsiveness to an erbb receptor tyrosine kinase inhibitor |
| JP2005024385A (ja) | 2003-07-02 | 2005-01-27 | Matsushita Electric Ind Co Ltd | 感圧センサ |
| EP1653986A4 (en) * | 2003-08-01 | 2007-03-14 | Smithkline Beecham Corp | TREATMENT OF P95 ERBB2 EXPRESSIVE CARCINOMA |
| ES2537631T3 (es) * | 2004-05-27 | 2015-06-10 | The Regents Of The University Of Colorado | Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer |
| WO2006063042A2 (en) * | 2004-12-07 | 2006-06-15 | Genentech, Inc. | Selecting patients for therapy with a her inhibitor |
| US20060204505A1 (en) * | 2005-03-08 | 2006-09-14 | Sliwkowski Mark X | Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs) |
| AR056857A1 (es) * | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
-
2007
- 2007-11-28 EP EP07846863.4A patent/EP2097754B2/en active Active
- 2007-11-28 EP EP12176507A patent/EP2518508A1/en not_active Withdrawn
- 2007-11-28 WO PCT/EP2007/010335 patent/WO2008064884A1/en not_active Ceased
- 2007-11-28 CA CA2670522A patent/CA2670522C/en active Active
- 2007-11-28 AU AU2007324868A patent/AU2007324868B2/en active Active
- 2007-11-28 JP JP2009538639A patent/JP5656406B2/ja active Active
- 2007-11-28 US US12/516,682 patent/US20100047829A1/en not_active Abandoned
-
2016
- 2016-02-18 US US15/047,041 patent/US10365283B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010510784A5 (https=) | ||
| Qian et al. | Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma | |
| JP5656406B2 (ja) | 治療効力を予測するためのマーカーとしての活性化ｈｅｒ３ | |
| Resnick et al. | Epidermal growth factor receptor, c-MET, β-catenin, and p53 expression as prognostic indicators in stage II colon cancer: a tissue microarray study | |
| Kazemi et al. | VEGF121 and VEGF165 differentially promote vessel maturation and tumor growth in mice and humans | |
| Schmitz et al. | Window of opportunity studies: do they fulfil our expectations? | |
| Lee et al. | Effect of simvastatin plus cetuximab/irinotecan for KRAS mutant colorectal cancer and predictive value of the RAS signature for treatment response to cetuximab | |
| Zhu et al. | Neuropilin-1 is overexpressed in osteosarcoma and contributes to tumor progression and poor prognosis | |
| JP2014503821A (ja) | 抗体ベースのアレイを用いる悪性がんの療法のための薬剤選択 | |
| US20130225541A1 (en) | Elevated PSMA Identifies Lethal Prostate Cancers | |
| Johnson et al. | Preliminary results from a prospective trial of preoperative combined BRAF and MEK-targeted therapy in advanced BRAF mutation-positive melanoma | |
| Millanta et al. | Immunohistochemical expression of COX-2, mPGES and EP2 receptor in normal and reactive canine bone and in canine osteosarcoma | |
| JP2016517960A5 (https=) | ||
| JP5413818B2 (ja) | 蛍光多重染色による蛋白定量法 | |
| Jia et al. | Update on biomarkers in development of anti-angiogenic drugs in gastric cancer | |
| Kossatz et al. | PARP1 as a biomarker for early detection and intraoperative tumor delineation in epithelial cancers–first-in-human results | |
| Überall et al. | Tumor autophagy is associated with survival outcomes in patients with resected non-small cell lung cancer | |
| JP2011527575A5 (https=) | ||
| George | Sunitinib, a multitargeted tyrosine kinase inhibitor, in the management of gastrointestinal stromal tumor | |
| CN103562722A (zh) | 一种区分甲状腺癌变的方法、实施该方法的试剂盒以及金属硫蛋白在区分甲状腺癌变中的用途 | |
| Dlamini | Navigating Melanoma Treatment Challenges: Next-generation Strategies and Solutions | |
| Cherciu et al. | Targeted Confocal Laser Endomicroscopy (CLE) for the Assessment of Putative Cancer Stem Cell Markers in Colorectal cancer-A Pilot Study | |
| JP7246731B2 (ja) | 膵癌の予後マーカー、膵癌の予後診断キット及び膵癌の予後を予測するための方法 | |
| RU2585122C1 (ru) | Способ прогнозирования метастазов в печени при раке прямой кишки | |
| ES2527926T5 (es) | HER3 activado como marcador para predecir la eficacia terapéutica |